Boston Scientific Corporation filings document the regulatory record of a global medical technology company with device and therapy portfolios for cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Recent 8-K reports furnish operating results, clinical-trial announcements and other material events tied to products such as WATCHMAN and EKOS.
Proxy and governance filings cover director elections, executive compensation, stockholder votes, board committee matters and amendments to the company’s certificate of incorporation. Additional disclosures address capital resources and financing arrangements, including revolving credit terms, along with common-stock reporting, senior debt references, risk-related governance and formal exhibits filed under the Exchange Act.
Boston Scientific Corp Chairman, President & CEO Michael F. Mahoney reported multiple equity award and vesting transactions. On February 13, 2026, he acquired 132,190 shares of common stock as a grant and another 8,832 shares through the conversion of restricted stock units, while 132,099 shares of common stock were withheld at $74.73 per share to cover tax obligations.
On February 14, 2026, 16,524 restricted stock units converted into 16,524 common shares, with 7,990 shares withheld for taxes at $74.73 per share. On February 16, 2026, 16,265 restricted stock units converted into common stock and 7,865 shares were similarly withheld for taxes at $74.73 per share.
The filing notes performance share units granted in February 2023 under organic net sales and total shareholder return programs, for which performance and service conditions were satisfied as of February 13, 2026. An additional 213,679 common shares are reported as held indirectly by trust.
Boston Scientific executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported multiple stock-based compensation transactions. He acquired Boston Scientific common stock through exercises of restricted stock units and performance share units, as well as grants totaling 34,898 shares of common stock on February 13, 2026.
On February 13, 14, and 16, 2026, he also had shares of common stock withheld to satisfy tax liabilities, disposing of 33,104, 1,990, and 1,806 shares at $74.73 per share, respectively, as tax-withholding dispositions rather than open-market sales. After these transactions, he directly held 213,907 shares of common stock, and 5,234 additional shares were reported as held indirectly by his child, for which he disclaims beneficial ownership.
Boston Scientific EVP Arthur C. Butcher reported multiple equity transactions in company stock and units. On February 13, 2026, he acquired 25,380 shares of common stock in two grant or award acquisitions, and also acquired shares through exercises of restricted stock units tied to long‑term incentive programs. He disposed of 25,150 shares of common stock on February 13, 2026 and smaller amounts on later dates to cover tax liabilities at $74.73 per share. Following these moves, he directly held 55,792 shares of common stock and indirectly held 13,354 shares through the company 401(k) plan.
Boston Scientific EVP, GC and Corporate Secretary Vance R. Brown reported multiple equity compensation transactions. On February 13–16, 2026, he acquired Boston Scientific common stock through the exercise and conversion of restricted stock units and performance share units, and through grants and awards, all at a stated price of $0.00 per share.
On these dates, shares of common stock were also disposed of at $74.73 per share to satisfy tax liabilities by delivering securities. Footnotes explain that performance share units granted on February 14, 2023 vested based on three-year total shareholder return and organic net sales performance through December 31, 2025, subject to a three-year service period satisfied on February 13, 2026. Each restricted stock unit represents a commitment to issue one share in four equal annual installments beginning on specified anniversaries of the grant dates.
Boston Scientific SVP and Chief HR Officer Miriam O'Sullivan reported several equity compensation transactions dated February 12, 2026. She acquired 961 shares of Boston Scientific common stock at $0.0000 through the exercise of restricted stock units, then had 338 shares withheld at $74.12 per share to cover tax obligations, leaving 15,420 directly held shares plus 1,731 held indirectly by her spouse.
On the derivative side, she exercised 961 restricted stock units, ending with 1,924 restricted stock units directly owned. She also received a new grant of 4,722 restricted stock units and a stock option award for 11,143 shares. The restricted stock units and options vest in four equal annual installments beginning on February 12, 2027, with the earlier RSU grant delivering shares in four equal installments starting February 12, 2025.
Boston Scientific SVP Emily Woodworth reported multiple equity awards and an RSU exercise. On February 12, 2026, she exercised 481 restricted stock units into 481 common shares at an exercise price of $0.0000 and had 242 shares withheld at $74.12 per share to cover tax obligations, leaving 951 common shares directly owned. She also received 6,071 new restricted stock units and a grant of 5,584 stock options with a $74.12 exercise price, each vesting in four equal annual installments starting February 12, 2027.
Boston Scientific executive Padraig Andrew O'Connor, EVP Global Operations, reported several equity compensation transactions dated February 12, 2026. He exercised 1,058 restricted stock units into common shares and had 457 shares withheld at $74.12 per share to cover tax obligations, leaving 4,486 common shares directly owned.
He now directly holds 2,116 restricted stock units from earlier awards. On the same date, he received a new grant of 5,059 restricted stock units and 11,939 stock options. The RSUs and options vest in four equal annual installments beginning on February 12, 2027, with each unit or option tied to one share of common stock.
Boston Scientific EVP and CFO Jonathan Monson reported several equity transactions on February 12, 2026. He exercised 1,154 restricted stock units into common shares at a conversion price of $0.0000, then had 573 common shares withheld at $74.12 per share to cover tax obligations, leaving 35,870 common shares held directly.
Monson also acquired new equity awards. He received 11,805 restricted stock units, each representing one future share of Boston Scientific common stock, and was granted stock options for 27,857 shares. Both the new RSUs and options vest in four equal annual installments beginning February 12, 2027.
Boston Scientific Chairman, President & CEO Michael F. Mahoney reported several equity compensation transactions dated February 12, 2026. He acquired 13,704 shares of common stock through the exercise of restricted stock units at $0.0000 per share, then disposed of 6,626 shares at $74.12 per share to cover tax obligations, leaving 1,418,813 common shares held directly.
Mahoney also received a new grant of 55,652 restricted stock units and a stock option for 131,329 shares with an exercise price of $74.12 per share, both vesting in four equal annual installments beginning February 12, 2027. In addition, 213,679 common shares are held indirectly in a trust.
Boston Scientific EVP & Group President, Cardiology Joseph Michael Fitzgerald reported equity compensation and related share movements. On February 12, 2026, he exercised 3,462 restricted stock units, receiving the same number of Boston Scientific common shares. To cover tax obligations, 1,612 common shares were disposed of at $74.12 per share through share withholding, leaving him with 169,892 common shares held directly. He also received new awards of 18,550 restricted stock units and a stock option for 43,776 shares, each vesting in four equal annual installments beginning on February 12, 2027. Following these transactions, he directly holds 6,924 restricted stock units and 18,550 restricted stock units from the new grant, plus the 43,776-share stock option. An additional 5,234 common shares are reported as held indirectly by his child, and he disclaims beneficial ownership of those shares.